[
  {
    "ts": null,
    "headline": "Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3",
    "summary": "BOSTON, February 17, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen’s 46th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, March 3, 2026, at 9:10 a.m. ET.",
    "url": "https://finnhub.io/api/news?id=c6c5323f44e41db7375e367d6b9055bc8ee4e4fd35c3820733b96ece0fece014",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771362000,
      "headline": "Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3",
      "id": 139126650,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, February 17, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen’s 46th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, March 3, 2026, at 9:10 a.m. ET.",
      "url": "https://finnhub.io/api/news?id=c6c5323f44e41db7375e367d6b9055bc8ee4e4fd35c3820733b96ece0fece014"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock",
    "summary": "Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=6b656806ef4847962b1642d5b6534169d56fdfee9d6cd39612a0275540f7f647",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771336804,
      "headline": "Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock",
      "id": 139124080,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=6b656806ef4847962b1642d5b6534169d56fdfee9d6cd39612a0275540f7f647"
    }
  },
  {
    "ts": null,
    "headline": "10 Health Care Stocks With Whale Alerts In Today's Session",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=bc69404b67565b1e405444a3527ed916cb98692284a20d4aec92df712a69cb1b",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771335327,
      "headline": "10 Health Care Stocks With Whale Alerts In Today's Session",
      "id": 139133638,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=bc69404b67565b1e405444a3527ed916cb98692284a20d4aec92df712a69cb1b"
    }
  },
  {
    "ts": null,
    "headline": "Canaccord Genuity Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $441",
    "summary": "Canaccord Genuity  analyst Whitney Ijem   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and raises the price target from $411 to $441.",
    "url": "https://finnhub.io/api/news?id=cd373b966436e03475c4a1d175b4247d0b70090ae1bf62939de583436d16f39f",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771329449,
      "headline": "Canaccord Genuity Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $441",
      "id": 139134947,
      "image": "",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": "Canaccord Genuity  analyst Whitney Ijem   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and raises the price target from $411 to $441.",
      "url": "https://finnhub.io/api/news?id=cd373b966436e03475c4a1d175b4247d0b70090ae1bf62939de583436d16f39f"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $607",
    "summary": "Barclays  analyst Eliana Merle   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $606 to $607.",
    "url": "https://finnhub.io/api/news?id=f91905510a6469716190d1a4e0412f0a465b542c2a664962dd69231f891f278f",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771328966,
      "headline": "Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $607",
      "id": 139134948,
      "image": "",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": "Barclays  analyst Eliana Merle   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $606 to $607.",
      "url": "https://finnhub.io/api/news?id=f91905510a6469716190d1a4e0412f0a465b542c2a664962dd69231f891f278f"
    }
  },
  {
    "ts": null,
    "headline": "Micron To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Tuesday",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=a9777e812b58884e43d7b1c467edb709b9b552f63364ff676809fa65cefefacd",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771319542,
      "headline": "Micron To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Tuesday",
      "id": 139121955,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/17/Micron-Technology-Inc--Logo-On-Smartphon.jpeg?width=2048&height=1536",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=a9777e812b58884e43d7b1c467edb709b9b552f63364ff676809fa65cefefacd"
    }
  },
  {
    "ts": null,
    "headline": "HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $591",
    "summary": "HC Wainwright &amp; Co.  analyst Andrew S. Fein   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $518 to $591.",
    "url": "https://finnhub.io/api/news?id=adf4cbcba987de4e5bb9fe96efef2fd12ec8e0d16552e4d186755447a781725f",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771315611,
      "headline": "HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $591",
      "id": 139122899,
      "image": "",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": "HC Wainwright &amp; Co.  analyst Andrew S. Fein   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $518 to $591.",
      "url": "https://finnhub.io/api/news?id=adf4cbcba987de4e5bb9fe96efef2fd12ec8e0d16552e4d186755447a781725f"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?",
    "summary": "Vertex Pharmaceuticals’ stock has lagged behind the broader market over the past year, but analysts remain moderately bullish about its prospects.",
    "url": "https://finnhub.io/api/news?id=0bedba502a0b8e410f472e1c7cd42ead8469414e4b32f544642ba1bd42bbad1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771305700,
      "headline": "Vertex Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?",
      "id": 139120672,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals’ stock has lagged behind the broader market over the past year, but analysts remain moderately bullish about its prospects.",
      "url": "https://finnhub.io/api/news?id=0bedba502a0b8e410f472e1c7cd42ead8469414e4b32f544642ba1bd42bbad1b"
    }
  }
]